Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | HPGD | P15428 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.44 |
| ▸ | SPR | P35270 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6345281 | 0.89 | ALDH1A1 (0.46) | ALDH1A1HPGDKDM4ESPRMAPT | |
| SCHEMBL6351972 | 0.85 | MAPT (0.41) | ALDH1A1HPGDKDM4EMAPTPARP1 | |
| SCHEMBL6354124 | 0.84 | MAPT (0.41) | ALDH1A1HPGDKDM4EMAPTMAPK1 | |
| SCHEMBL6340087 | 0.84 | MAPT (0.42) | ALDH1A1HPGDKDM4EMAPTMAPK1 | |
| Hydrochloric Acid SCHEMBL6342923 | 0.83 | MAPT (0.42) | ALDH1A1HPGDKDM4EMAPTHTT | |
| SCHEMBL6339985 | 0.81 | L3MBTL1 (0.43) | ALDH1A1HPGDMAPTMAPK1HSD17B10 | |
| SCHEMBL6353735 | 0.79 | SPR (0.42) | ALDH1A1HPGDKDM4ESPRMAPT | |
| SCHEMBL6345178 | 0.79 | DYRK1A (0.45) | ALDH1A1HPGDKDM4ESPRMAPT | |
| SCHEMBL6350635 | 0.78 | MAPT (0.39) | ALDH1A1HPGDKDM4EMAPTHTT | |
| SCHEMBL6341115 | 0.75 | MEN1 (0.45) | ALDH1A1HPGDKDM4ESPRMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6949648-B2 | Condensed pyrazole derivatives, process for producing the same and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-09-27 | — | — | US | disclosed |
| US-20030187014-A1 | Condensed pyrazole derivatives, process for producing the same and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-10-02 | — | — | US | disclosed |
| EP-1270572-A1 | CONDENSED PYRAZOLE DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND USE THEREOF | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2003-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030187014-A1 | Condensed pyrazole derivatives, process for producing the same and use thereof | PTGS1, PTGIS, IL5 | ALDH1A1 1061/4885HPGD 19/4885KDM4E 1741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.